174 related articles for article (PubMed ID: 38007537)
1. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
[TBL] [Abstract][Full Text] [Related]
2. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.
Luo K; Li L; Li Y; Wu C; Yin Y; Chen Y; Deng M; Nowsheen S; Yuan J; Lou Z
Genes Dev; 2016 Dec; 30(23):2581-2595. PubMed ID: 27941124
[TBL] [Abstract][Full Text] [Related]
3. DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects.
Jegadesan NK; Branzei D
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33879618
[No Abstract] [Full Text] [Related]
4. A novel UCHL
Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
[TBL] [Abstract][Full Text] [Related]
5. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
Maeda J; Haskins JS; Kato TA
Mutat Res; 2023; 826():111815. PubMed ID: 36812659
[TBL] [Abstract][Full Text] [Related]
6. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
[TBL] [Abstract][Full Text] [Related]
7. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
8. Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.
Lodhia KA; Gao S; Aleksic T; Esashi F; Macaulay VM
Int J Cancer; 2015 Jun; 136(12):2961-6. PubMed ID: 25388513
[TBL] [Abstract][Full Text] [Related]
9. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition.
Bishara LA; Machour FE; Awwad SW; Ayoub N
DNA Repair (Amst); 2021 Jan; 97():103025. PubMed ID: 33248388
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
11. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
Clements KE; Schleicher EM; Thakar T; Hale A; Dhoonmoon A; Tolman NJ; Sharma A; Liang X; Imamura Kawasawa Y; Nicolae CM; Wang HG; De S; Moldovan GL
Nat Commun; 2020 Nov; 11(1):6118. PubMed ID: 33257658
[TBL] [Abstract][Full Text] [Related]
12. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
[TBL] [Abstract][Full Text] [Related]
13. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
14. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Stoepker C; Faramarz A; Rooimans MA; van Mil SE; Balk JA; Velleuer E; Ameziane N; Te Riele H; de Winter JP
DNA Repair (Amst); 2015 Feb; 26():54-64. PubMed ID: 25583207
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
16. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
17. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]